LDT for Thyroid Cancer Now Reimbursed for Over 110 Million Patients

by

Company press release: Veracyte Receives Aetna Coverage for Its Afirma® Gene Expression Classifier for Use in Thyroid Cancer Diagnosis.

The Afirma® test offered by Veracyte measures 142 genes by RNA expression array (manufactured by Affymetrix) to provide the likelihood that thyroid nodules of indeterminate nature (as classified by a cytopathologist) are cancerous and thus deserving of surgical intervention.

PageLines

Real-Time COVID R&D Tracking

As COVID-19 infections continue to spread, organizations with technologies or devices that can support new drug, vaccine, or test development have a life-saving contribution to make. The Amplion Intelligence Platform can alert you to new COVID-19 trial activities in real-time and automatically match you to partners who need your unique capabilities immediately. It’s already tomorrow somewhere, so let us help you start today.  Learn More

Request Access